Similar articles

• Postmarketing re-evaluation of irinotecan plus 5-fluorouracil/leucovorin for first-line treatment of metastatic colorectal cancer.

  Chico IM, Pazdur R. Chico IM, et al. Clin Colorectal Cancer. 2002 May;2(1):11-2. doi: 10.1016/S1533-0028(11)70495-9. Clin Colorectal Cancer. 2002. PMID: 12453329 No abstract available.
• Irinotecan/5-fluorouracil/leucovorin in advanced colorectal cancer: Oncologic Drugs Advisory committee summary.

  Oncologic Drugs Advisory Committee. Oncologic Drugs Advisory Committee. Clin Colorectal Cancer. 2002 May;2(1):8-10. Clin Colorectal Cancer. 2002. PMID: 12453328 No abstract available.
• [Irinotecan plus fluorouracil and leucovorin for advanced colorectal cancer].

  Motomura S. Motomura S. Nihon Rinsho. 2003 Sep;61 Suppl 7:360-3. Nihon Rinsho. 2003. PMID: 14574913 Review. Japanese. No abstract available.
• [Initial results of randomized studies of metastatic colorectal carcinoma urge careful and controlled use of CPT-11].

  Klautke G, Fietkau R. Klautke G, et al. Strahlenther Onkol. 2002 Mar;178(3):163-4. Strahlenther Onkol. 2002. PMID: 11962194 German. No abstract available.
• Improving the toxicity of irinotecan/5-FU/leucovorin: a 21-day schedule.

  Hwang JJ, Eisenberg SG, Marshall JL. Hwang JJ, et al. Oncology (Williston Park). 2003 Sep;17(9 Suppl 8):37-43. Oncology (Williston Park). 2003. PMID: 14569847 Review.